Trevi Therapeutics (TRVI) Income towards Parent Company (2018 - 2026)

Trevi Therapeutics' Income towards Parent Company history runs 9 years deep, the most recent figure standing at -$13.2 million for Q1 2026.

• In Q1 2026, Income towards Parent Company fell 27.58% year-over-year to -$13.2 million; the TTM figure through Mar 2026 stood at -$45.6 million (up 3.58% YoY), while the FY2025 annual figure was -$42.8 million, up 10.67% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$13.2 million, down from -$8.3 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$5.5 million in Q4 2022, with the low at -$13.2 million in Q3 2024.
• The 5-year median for Income towards Parent Company is -$8.3 million (2025), against an average of -$9.5 million.
• The sharpest annual moves came in 2022 and 2024: Income towards Parent Company surged 35.39% in 2022, then slumped 72.88% in 2024.
• Trevi Therapeutics' Income towards Parent Company stood at -$5.5 million in 2022, then tumbled by 42.07% to -$7.8 million in 2023, then sank by 45.29% to -$11.4 million in 2024, then grew by 26.86% to -$8.3 million in 2025, then tumbled by 58.73% to -$13.2 million in 2026.
• Business Quant data shows TRVI's Income towards Parent Company at -$13.2 million in Q1 2026, -$8.3 million in Q4 2025, and -$11.8 million in Q3 2025.